232 related articles for article (PubMed ID: 26377682)
21. Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
Mutesa L; Pierquin G; Janin N; Segers K; Thomée C; Provenzi M; Bours V
Cancer Genet Cytogenet; 2008 Apr; 182(1):40-2. PubMed ID: 18328949
[TBL] [Abstract][Full Text] [Related]
22. Noonan syndrome, the Ras-MAPK signalling pathway and short stature.
Binder G
Horm Res; 2009 Apr; 71 Suppl 2():64-70. PubMed ID: 19407499
[TBL] [Abstract][Full Text] [Related]
23. Recurrent ganglioneuroma in PTPN11-associated Noonan syndrome: A case report and literature review.
Morales-Rosado JA; Singh H; Olson RJ; Larsen BT; Hager MM; Klee EW; Dhamija R
Am J Med Genet A; 2021 Jun; 185(6):1883-1887. PubMed ID: 33779033
[TBL] [Abstract][Full Text] [Related]
24. Extensive abdominal lipomatosis in a patient with Noonan/LEOPARD syndrome (Noonan syndrome-Multiple Lentigines).
Piard J; Verloes A; Cavé H; Peuchmaur M; Bennaceur S; Leheup B
Am J Med Genet A; 2012 Jun; 158A(6):1406-10. PubMed ID: 22528600
[TBL] [Abstract][Full Text] [Related]
25. Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype.
Ekvall S; Hagenäs L; Allanson J; Annerén G; Bondeson ML
Am J Med Genet A; 2011 Jun; 155A(6):1217-24. PubMed ID: 21548061
[TBL] [Abstract][Full Text] [Related]
26. Noonan syndrome: relationships between genotype, growth, and growth factors.
Limal JM; Parfait B; Cabrol S; Bonnet D; Leheup B; Lyonnet S; Vidaud M; Le Bouc Y
J Clin Endocrinol Metab; 2006 Jan; 91(1):300-6. PubMed ID: 16263833
[TBL] [Abstract][Full Text] [Related]
27. Growth and Growth Hormone Treatment in Noonan Syndrome.
Romano AA
Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):459-464. PubMed ID: 31115197
[TBL] [Abstract][Full Text] [Related]
28. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
Brasil AS; Pereira AC; Wanderley LT; Kim CA; Malaquias AC; Jorge AA; Krieger JE; Bertola DR
Genet Test Mol Biomarkers; 2010 Jun; 14(3):425-32. PubMed ID: 20578946
[TBL] [Abstract][Full Text] [Related]
29. [Arnold-Chiari malformation in Noonan syndrome and other syndromes of the RAS/MAPK pathway].
Ejarque I; Millán-Salvador JM; Oltra S; Pesudo-Martínez JV; Beneyto M; Pérez-Aytés A
Rev Neurol; 2015 May; 60(9):408-12. PubMed ID: 25912702
[TBL] [Abstract][Full Text] [Related]
30. Abnormal growth in noonan syndrome: the challenge of optimal therapy.
Savage MO; Padidela R; Kirk JM; Malaquias AC; Jorge AA
Pediatr Endocrinol Rev; 2009 Jun; 6 Suppl 4():523-8. PubMed ID: 19550387
[TBL] [Abstract][Full Text] [Related]
31. Impact of Growth Hormone Therapy on Adult Height in Patients with PTPN11 Mutations Related to Noonan Syndrome.
Malaquias AC; Noronha RM; Souza TTO; Homma TK; Funari MFA; Yamamoto GL; Silva FV; Moraes MB; Honjo RS; Kim CA; Nesi-França S; Carvalho JAR; Quedas EPS; Bertola DR; Jorge AAL
Horm Res Paediatr; 2019; 91(4):252-261. PubMed ID: 31132774
[TBL] [Abstract][Full Text] [Related]
32. GH Therapy and first final height data in Noonan-like syndrome with loose anagen hair (Mazzanti syndrome).
Mazzanti L; Tamburrino F; Scarano E; Perri A; Vestrucci B; Guidetti M; Rossi C; Tartaglia M
Am J Med Genet A; 2013 Nov; 161A(11):2756-61. PubMed ID: 24124081
[TBL] [Abstract][Full Text] [Related]
33. Cochlear implantation and clinical features in patients with Noonan syndrome and Noonan syndrome with multiple lentigines caused by a mutation in PTPN11.
van Nierop JWI; van Trier DC; van der Burgt I; Draaisma JMT; Mylanus EAM; Snik AF; Admiraal RJC; Kunst HPM
Int J Pediatr Otorhinolaryngol; 2017 Jun; 97():228-234. PubMed ID: 28483241
[TBL] [Abstract][Full Text] [Related]
34. Hepatoblastoma in a Noonan syndrome patient with a PTPN11 mutation.
Yoshida R; Ogata T; Masawa N; Nagai T
Pediatr Blood Cancer; 2008 Jun; 50(6):1274-6. PubMed ID: 18253957
[TBL] [Abstract][Full Text] [Related]
35. The Growth Characteristics of Patients with Noonan Syndrome: Results of Three Years of Growth Hormone Treatment: A Nationwide Multicenter Study.
Şıklar Z; Genens M; Poyrazoğlu Ş; Baş F; Darendeliler F; Bundak R; Aycan Z; Savaş Erdeve Ş; Çetinkaya S; Güven A; Abalı S; Atay Z; Turan S; Kara C; Can Yılmaz G; Akyürek N; Abacı A; Çelmeli G; Sarı E; Bolu S; Korkmaz HA; Şimşek E; Çatlı G; Büyükinan M; Çayır A; Evliyaoğlu O; İşgüven P; Özgen T; Hatipoğlu N; Elhan AH; Berberoğlu M
J Clin Res Pediatr Endocrinol; 2016 Sep; 8(3):305-12. PubMed ID: 27125300
[TBL] [Abstract][Full Text] [Related]
36. Expanding the genetic spectrum of Noonan syndrome.
Noordam K
Horm Res; 2007; 68 Suppl 5():24-7. PubMed ID: 18174700
[TBL] [Abstract][Full Text] [Related]
37. Growth hormone therapy in Noonan syndrome: growth response and characteristics.
Westphal O
Horm Res; 2009 Dec; 72 Suppl 2():41-5. PubMed ID: 20029236
[TBL] [Abstract][Full Text] [Related]
38. Mutational analysis of the PTPN11 gene in Egyptian patients with Noonan syndrome.
Essawi ML; Ismail MF; Afifi HH; Kobesiy MM; El Kotoury A; Barakat MM
J Formos Med Assoc; 2013 Nov; 112(11):707-12. PubMed ID: 24183200
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Effectiveness and Safety of Childhood Growth Hormone Treatment in Noonan Syndrome.
Rohrer TR; Abuzzahab J; Backeljauw P; Birkegård AC; Blair J; Dahlgren J; Júlíusson PB; Ostrow V; Pietropoli A; Polak M; Romano A; Ross J; Sävendahl L; Miller BS
Horm Res Paediatr; 2020; 93(6):380-395. PubMed ID: 33440388
[TBL] [Abstract][Full Text] [Related]
40. Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
Yagasaki H; Nakane T; Hasebe Y; Watanabe A; Kise H; Toda T; Koizumi K; Hoshiai M; Sugita K
Am J Med Genet A; 2015 Dec; 167A(12):3144-7. PubMed ID: 26286251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
